Development of an HTS assay for the search of anti-influenza agents targeting the interaction of viral RNA with the NS1 protein

Journal of Biomolecular Screening

Volumn 13, Issue 7, 2008, Pages 581-590

  Maroto, Marta ^a   Fernandez, Yolanda ^b,c   Ortin, Juan ^b,c   Pelaez, Fernando ^a   Cabello, M Angerles ^a  

^a Medical affairs Merck sharp and Dohme ltd   (Spain)

^b CENTRO NACIONAL DE BIOTECNOLOGÍA   (Spain)

^c INSTITUTO DE SALUD CARLOS III   (Spain)

Author keywords

Flashplate; Influenza; NS1; Viral RNA

Indexed keywords

ANTIINFLUENZA AGENT; ANTIVIRUS AGENT; HISTIDINE; NONSTRUCTURAL PROTEIN 1; NUCLEOTIDE; RECOMBINANT PROTEIN; VIRUS RNA;

ARTICLE; AUTOMATION; BINDING ASSAY; CELL CULTURE; CELL STRAIN; CONCENTRATION RESPONSE; CONTROLLED STUDY; CYTOPATHOGENIC EFFECT; DRUG DETERMINATION; DRUG TARGETING; HIGH THROUGHPUT SCREENING; INFLUENZA; INFLUENZA VIRUS A; INHIBITION KINETICS; ISOTOPE LABELING; MATERIAL COATING; MOLECULAR PROBE; NONHUMAN; PHYSICAL CHEMISTRY; PLASMID; PRIORITY JOURNAL; PROCESS DEVELOPMENT; PROTEIN RNA BINDING; REDUCTION; TECHNOLOGY;

ANIMALS; ANTIVIRAL AGENTS; AUTOMATION; CELL LINE; DOGS; DOSE-RESPONSE RELATIONSHIP, DRUG; DRUG DESIGN; DRUG EVALUATION, PRECLINICAL; HUMANS; INFLUENZA, HUMAN; RECOMBINANT PROTEINS; RNA; TECHNOLOGY, PHARMACEUTICAL; VIRAL NONSTRUCTURAL PROTEINS; VIRUS REPLICATION;

INFLUENZA A VIRUS; ORTHOMYXOVIRIDAE;

EID: 49249137457     PISSN: 10870571     EISSN: 1552454X     Source Type: Journal    
DOI: 10.1177/1087057108318754     Document Type: Article

References (38)

1. Stohr K.: Preventing and treating influenza. Br Med J 2003 ; 326: 1223-1224.
2. Kawaoka Y., Krauss S., Webster RG: Avian-to-human transmission of the PB1 gene of influenza A viruses in the 1957 and 1968 pandemics. J Virol 1989 ; 63: 4603-4608.
3. De Jong JC, Claas EC, Osterhaus AD, Webster RG, Lim WL: A pandemic warning ? Nature 1997 ; 389: 554.
4. Webby RJ, Webster RG: Are we ready for pandemic influenza ? Science 2003 ; 302: 1519-1522.
5. Harper SA, Fukuda K., Uyeki TM, Cox JJ, Bridges CB: Prevention and control of influenza: recommendations of the Advisory Committee on Immunization Practices (ACIP). MMWR Recom Rep 2004 ; 53: 1-40.
6. Hay AJ, Wolstenholme AJ, Skehel JJ, Smith MH: The molecular basis of the specific anti-influenza action of amantadine. EMBO J 1985 ; 4: 3021-3024.
7. Gubareva LV, Penn CR, Webster RG: Inhibition of replication of avian influenza viruses by the neuraminidase inhibitor 4-guanidino-2,4-dideoxy-2,3- dehydro-N-acetylneuraminic acid. Virology 1995 ; 212: 323-330.
8. Wu MJ, Ing TS, Soung LS, Daugirdas JT, Hano JE, Gandhi VC: Amantadine hydrochloride pharmacokinetics in patients with impaired renal function. Clin Nephrol 1982 ; 17: 19-23.
9. Van Voris LP, Betts RF, Hayden FG, Christmas WA, Douglas RG Jr: Successful treatment of naturally occurring influenza A/USSR/77 H1N1. JAMA 1981 ; 245: 1128-1131.
10. Cass LM, Efthymiopoulos C., Bye A.: Pharmacokinetics of zanamivir after intravenous, oral, inhaled or intranasal administration to healthy volunteers. Clin Pharmacokinet 1999 ; 36 (Suppl. 1). 1-11.
11. Hayden FG, Treanor JJ, Fritz RS, Lobo M., Betts RF, Miller M.,, et al. Use of the oral neuraminidase inhibitor oseltamivir in experimental human influenza: randomized controlled trials for prevention and treatment. JAMA 1999 ; 282: 1240-1246.
12. Monto AS, Arden NH: Implications of viral resistance to amantadine in control of influenza A. Clin Infect Dis 1992 ; 15: 362-367.
13. Hall CB, Dolin R., Gala CL, Markovitz DM, Zhang YQ, Madore PH,, et al. Children with influenza A infection: treatment with rimantadine. Pediatrics 1987 ; 80: 275-282.
14. Kiso M., Mitamura K., Sakai-TagawaY., Shiraishi K., Kawakami C., Kimura K.,, et al. Resistant influenza A viruses in children treated with oseltamivir: descriptive study. Lancet 2004 ; 364: 759-765.
15. Toogood PL, Galliker PK, Glick GD, Knowles JR: Monovalent sialosides that bind tightly to influenza A virus. J Med Chem 1991 ; 34: 3138-3140.
16. Choi SK, Mammen M., Whitesides GM: Monomeric inhibitors of influenza neuraminidase enhance the hem agglutination inhibition activities of polyacrylamides presenting multiple C-sialoside groups. Chem Biol 1996 ; 3: 97-104.
17. Parkes KE, Ermert P., Fassler J., Ives J., Martin JA, Merrett JH,, et al. Use of a pharmacophore mode to discover a new class of influenza endonuclease inhibitors. J Med Chem 2003 ; 46: 1153-1164.
18. Tomassini JE, Selnick H., Davies ME, Armstrong ME, Baldwin J., Bourgeois M.,, et al. Inhibition of cap (m7GpppXm)-dependent endonuclease of influenza virus by 4-substituted 2.4-dioxobutanoid acid compounds. Antimicrob Agents Chemother 1994 ; 38: 2827-2837.
19. Tomassini JE, Davies ME, Hastings JC, Lingham R., Mojena M., Raghoobar SL,, et al. A novel antiviral agent which inhibits the endonuclease of influenza viruses. Antimicrob Agents Chemother 1996 ; 40: 1189-1193.
20. Klumpp K., Hang JQ, Rajendran S., Yang Y., Derosier A., Wong Kai In P.,, et al. Two-metal ion mechanism of RNA cleavage by HIV RNase H and mechanism-based design of selective HIV RNase H inhibitors. Nucleic Acids Res 2003 ; 31: 6852-6859.
21. Katze MG, Krug RM: Metabolism and expression of RNA polymerase II transcripts in influenza virus infected cells. Mol Cell Biol 1984 ; 4: 2198-2206.
22. Beloso A., Martínez C., Valcárcel J., Fernández- Santarén J., Ortín J.: Degradation of cellular mRNA during influenza virus infection: its possible role in protein synthesis shutoff. J Gen Virol 1992 ; 73: 575-581.
23. Ortín J.: Multiple levels of posttranscriptional regulation of influenza virus gene expression. Semin Virol 1998 ; 8: 335-342.
24. Falcón AM, Fortes P., Marión RM, Beloso A., Ortín J.: Interaction of influenza virus NS1 protein and the human homologue of Staufen in vivo and in vitro. Nucleic Acids Res 1999 ; 27: 2241-2247.
25. Fortes P., Beloso A., Ortín J.: Influenza virus NS1 protein inhibits premRNA splicing and blocks mRNA nucleocytoplasmic transport. EMBO J 1994 ; 13: 704-712.
26. Fortes P., Lamond AI, Ortín J.: Influenza virus NS1 protein alters the subnuclear localization of cellular splicing components. J Gen Virol 1995 ; 76: 1001-1007.
27. De la Luna S., Fortes P., Beloso A., Ortín J.: Influenza virus NS1 protein enhances the rate of translation initiation of viral mRNAs. J Virol 1995 ; 69: 2427-2433.
28. Marión RM, Aragón T., Beloso A., Nieto A., Ortín J.: The N-terminal half of the influenza virus NS1 protein is sufficient for nuclear retention of mRNA and enhancement of viral mRNA translation. Nucleic Acids Res 1997 ; 25: 4271-4277.
29. Marión RM, Fortes P., Beloso A., Dotti C., Ortín, J.: A human sequence homologue of Staufen is an RNA-binding protein that is associated with polysomes and localizes to the rough endoplasmic reticulum. Mol Cell Biol 1999 ; 19: 2212-2219.
30. Perales B., Ortín J.: The influenza A virus PB2 polymerase subunit is required for the replication of viral RNA. J Virol 1997 ; 71: 1381-1385.
31. Zhang J-H., Chung TDY, Oldenburg KR: A simple statistical parameter for use in evaluation and validation of high throughput screening assays. J Biomol Screen 1999 ; 4: 67-73.
32. Hamasaki K., Ueno A.: Aminoglycoside antibiotics, neamine and its derivatives as potent inhibitors for the RNA-protein interactions derived from HIV-1 activators. Bioorg Med Chem Lett 2001 ; 11: 591-594.
33. Lapidot A., Vijayabaskar V., Litovchick A., Yu J., James TL: Structure-activity relationships of aminoglycoside-arginine conjugates that bind HIV-1 RNAs as determined by fluorescence and NMR spectroscopy. FEBS Lett 2004 ; 577: 415-421.
34. Xiao G., Kumar A., Li K., Rigl CT, Bajic M., Davis TM,, et al. Inhibition of the HIV-1 Rev-RRE complex formation by unfused aromatic cations. Bioorg Med Chem 2001 ; 9: 1097-1113.
35. Chapman RL, Stanley TB, Hazen R., Garvey EP: Small molecule modulators of HIV Rev/Rev response element interaction identified by random screening. Antiviral Res 2002 ; 54: 149-162.
36. Luedtke NW, Tor Y.: Fluorescence-based methods for evaluating the RNA affinity and specificity of HIV-1 Rev-RRE inhibitors. Biopolymers 2003 ; 70: 103-119.
37. Mills NL, Shelat AA, Guy RK: Assay optimization and screening of RNA-protein interactions by AlphaScreen. J Biomol Screen 2007 ; 12: 946-955.
38. Lipinski CA, Lombardo F., Dominy BW, Feeney PJ: "Experimental and computational approaches to estimate solubility and permeability in drug discovery and development settings." Adv Drug Deliv Rev 1997 ; 23: 3-25.